Last reviewed · How we verify
Active comparator: Niraparib
Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death.
Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and leading to cell death. Used for Recurrent ovarian cancer (BRCA-mutated and non-mutated), Maintenance treatment of ovarian cancer following platinum-based chemotherapy, HRD-positive ovarian cancer.
At a glance
| Generic name | Active comparator: Niraparib |
|---|---|
| Also known as | Niraparib |
| Sponsor | Tesaro, Inc. |
| Drug class | PARP inhibitor |
| Target | PARP1, PARP2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Niraparib is a PARP inhibitor that blocks PARP1 and PARP2, enzymes responsible for repairing single-strand DNA breaks. By inhibiting PARP, the drug causes accumulation of DNA damage in cancer cells, particularly those with BRCA mutations or homologous recombination deficiency, triggering apoptosis. This mechanism is especially effective in ovarian and other cancers with impaired DNA repair pathways.
Approved indications
- Recurrent ovarian cancer (BRCA-mutated and non-mutated)
- Maintenance treatment of ovarian cancer following platinum-based chemotherapy
- HRD-positive ovarian cancer
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Fatigue
- Vomiting
- Constipation
- Leukopenia
Key clinical trials
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active comparator: Niraparib CI brief — competitive landscape report
- Active comparator: Niraparib updates RSS · CI watch RSS
- Tesaro, Inc. portfolio CI